Management of Intracranial Bleeding in Patients with Rheumatic Heart Disease and Atrial Fibrillation on Anticoagulation

Immediate Management

For a patient with rheumatic heart disease, mitral valve repair, and chronic atrial fibrillation on warfarin who develops intracranial bleeding, immediate reversal of anticoagulation with intravenous vitamin K and prothrombin complex concentrate is required, followed by consideration of restarting anticoagulation after 7-10 days with careful risk assessment 1, 2
Immediately reverse warfarin-associated coagulopathy with intravenous vitamin K to normalize the INR 1, 2
Administer prothrombin complex concentrate (PCC) for rapid reversal of anticoagulation, as it normalizes INR more quickly with lower fluid volumes than fresh frozen plasma (FFP) 1, 2
Consider neurosurgical consultation for evaluation of potential surgical intervention based on the size, location, and clinical impact of the hemorrhage 1, 2

Perform serial neurological examinations to detect any clinical deterioration 1, 2
Obtain repeat brain imaging to monitor hemorrhage size and assess for expansion 1, 2
Monitor vital signs closely with particular attention to blood pressure control, as hypertension can worsen intracranial bleeding 1, 2

The decision to restart anticoagulation must balance the risk of thromboembolism against the risk of recurrent intracranial hemorrhage 4, 5
For patients with high thromboembolic risk (mechanical valve or atrial fibrillation with prior stroke), warfarin therapy may be restarted 7-10 days after the onset of the original ICH 1, 2
Consider the location of the hemorrhage - lobar hemorrhages (suggesting possible amyloid angiopathy) have higher risk of recurrence than deep hemorrhages 4, 5

For patients with atrial fibrillation at lower risk of stroke but higher risk of bleeding, antiplatelet therapy may be a better alternative than warfarin 1, 2
Consider placement of a left atrial appendage closure device as an alternative to long-term anticoagulation in patients with non-valvular atrial fibrillation at high risk of bleeding 6

For patients with rheumatic heart disease and mitral valve repair who also have chronic atrial fibrillation, long-term anticoagulation is generally indicated due to high thromboembolic risk 6, 7
The presence of both rheumatic heart disease and atrial fibrillation significantly increases thromboembolic risk, making the decision to restart anticoagulation more compelling 6, 7

Avoid high-dose vitamin K1 routinely as it may create a hypercoagulable condition 7
Do not restart anticoagulation too early (before 7 days) as this increases the risk of hemorrhage expansion 1, 2
Avoid bridging with heparin when restarting anticoagulation as this may increase bleeding risk 7
Do not assume that all intracranial hemorrhages have the same recurrence risk - the etiology and location matter significantly 4, 5